SCHEMBL4158514

SCHEMBL4158514

CCOC(=O)c1c(O)c2ccsc2[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.55
KDM5B Q9UGL1 1/20 0.55
PARP15 Q460N3 3/20 0.49
TNKS2 Q9H2K2 3/20 0.49
PARP10 Q53GL7 2/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 1/20 0.47
ALDH1A1 P00352 4/20 0.47
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
PARP2 Q9UGN5 1/20 0.46
TNKS O95271 1/20 0.44
PARP1 P09874 1/20 0.44
APLNR P35414 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5113224 0.85 PARP15 (0.48) KDM5AKDM5BPARP15TNKS2PARP10
SCHEMBL4158228 0.80 KDM5A (0.56) KDM5AKDM5BKDM4ELMNAALDH1A1
SCHEMBL14208480 0.78 MEN1 (0.54) PARP15TNKS2PARP10LMNAALDH1A1
SCHEMBL4703123 0.77 KDM5A (0.60) KDM5AKDM5BKDM4ELMNAALDH1A1
SCHEMBL4155315 0.76 ALDH1A1 (0.50) KDM5AKDM5BKDM4ELMNAALDH1A1
SCHEMBL1058188 0.75 KDM5A (0.68) KDM5AKDM5BKDM4ELMNAALDH1A1
SCHEMBL5330015 0.75 KDM5A (0.64) KDM5AKDM5BKDM4EALDH1A1
SCHEMBL15966771 0.74 KDM5A (0.59) KDM5AKDM5BKDM4EALDH1A1GAA
SCHEMBL1242308 0.73 HPGD (0.43) PARP15TNKS2PARP10KDM4EALDH1A1
SCHEMBL5526950 0.73 KDM5A (0.62) KDM5AKDM5BKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US disclosed
US-20080139551-A1 TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES AVANIR PHARMACEUTICALS (US) 2008-06-12 US disclosed
US-7365200-B2 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-04-29 US disclosed
US-7365200-B2 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-04-29 US disclosed
US-7365200-B2 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS (US) 2008-04-29 US disclosed
EP-1861407-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-12-05 EP disclosed
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-08-02 US disclosed
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-08-02 US disclosed
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2007-08-02 US disclosed
US-20060229314-A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors AVANIR PHARMACEUTICALS 2006-10-12 US disclosed
WO-2006102191-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS AVANIR PHARMACEUTICALS (US) 2006-09-28 WO disclosed
EP-0505058-B1 Thienopyridine derivatives and pharmaceutical compositions containing them KYOWA HAKKO KOGYO KK (JP) 1997-05-21 EP disclosed
EP-0503844-B1 Thienopyridine derivatives and pharmaceutical compositions containing them KYOWA HAKKO KOGYO KK (JP) 1994-08-03 EP disclosed
US-5219864-A Prevention, treatment of osteoporosis KYOWA HAKKO KOGYO CO., LTD. (JP) 1993-06-15 US disclosed
US-5155115-A THIENOPYRIDINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-10-13 US disclosed
EP-0505058-A1 Thienopyridine derivatives and pharmaceutical compositions containing them KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-09-23 EP disclosed
EP-0503844-A1 Thienopyridine derivatives and pharmaceutical compositions containing them KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179149-A1 THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS MIF, MMP12, MSR1 KDM5A 2405/4885KDM5B 2307/4885PARP15 3706/4885
US-20080139551-A1 TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES TNF, TNFRSF1A, TNFRSF9 KDM5A 4732/4885KDM5B 4749/4885PARP15 4726/4885
US-20060229314-A1 Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors MIF, MMP12, MSR1 KDM5A 2405/4885KDM5B 2307/4885PARP15 3706/4885
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 KDM5A 495/4885KDM5B 588/4885PARP15 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.